Trending

GlaxoSmithKline

GSK cuts 650 jobs in the US

GlaxoSmithKline moves ahead with its planed cost saving strategy and cuts 650 jobs in North Carolina, according to

X

GSK cuts 650 jobs in the US

https://pharmaphorum.com/news/glaxosmithkline-cuts-650-jobs/

GSK’s Indian Horlicks sale may fetch over $4 billion

GlaxoSmithKline (GSK) has accelerated the review of its Horlicks business in India, hoping to sell it for over

X

GSK’s Indian Horlicks sale may fetch over $4 billion

https://pharmaphorum.com/news/gsk-indian-horlicks-sell-might-fetch-4-billion/

GSK appoints former HSBC exec Iain Mackay as CFO

GSK appoints former HSBC exec Iain Mackay as CFO

GlaxoSmithKline has appointed HSBC’s Iain Mackay as its next chief financial officer, replacing Simon Dingemans, who is to

X

GSK appoints former HSBC exec Iain Mackay as CFO

https://pharmaphorum.com/news/gsk-appoints-former-hsbc-exec-iain-mackay-cfo/

GSK signs $300m R&D deal with 23andMe

GlaxoSmithKline signed a $300 million research and development deal with mail gene profiling company 23andMe, gaining access to

X

GSK signs $300m R&D deal with 23andMe

https://pharmaphorum.com/r-d/gsk-welcomes-23andmes-dna-database/

GSK could split amid pressure from investors – report

GlaxoSmithKline’s chairman, Philip Hampton, may be considering splitting the company amid pressure from top investors to separate the

X

GSK could split amid pressure from investors – report

https://pharmaphorum.com/news/gsk-chairman-raises-break-prospect/

GSK’s blockbuster HIV drug linked with birth defects

GSK’s blockbuster HIV drug linked with birth defects

Regulators issue warning after preliminary study findings

X

GSK’s blockbuster HIV drug linked with birth defects

https://pharmaphorum.com/news/gsk-blockbuster-hiv-drug-linked-with-birth-defects/

FDA approves expanded use for GSK’s COPD triple therapy

FDA approves expanded use for GSK’s COPD triple therapy

GSK is aiming to revive its respiratory drugs franchise

X

FDA approves expanded use for GSK’s COPD triple therapy

https://pharmaphorum.com/news/fda-approves-expanded-use-for-gsks-copd-triple-therapy/

GSK to pay $13bn for Novartis stake in OTC joint venture

GSK to pay $13bn for Novartis stake in OTC joint venture

GlaxoSmithKline is to buy out Novartis from their over-the-counter joint venture, and may sell its Horlicks business to

X

GSK to pay $13bn for Novartis stake in OTC joint venture

https://pharmaphorum.com/news/gsk-wants-take-control-otc-joint-venture/

Verona to take COPD hopeful into phase 3

Verona to take COPD hopeful into phase 3

Verona Pharma is to take lung drug RPL554 into late clinical development after a successful phase 2b trial.

X

Verona to take COPD hopeful into phase 3

https://pharmaphorum.com/market-access-2/verona-to-take-copd-hopeful-into-phase-3/

1 2 3 4

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com